10,288 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Cetera Trust Company N.A

Cetera Trust Company N.A bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,288 shares of the medical research company's stock, valued at approximately $2,963,000. Amgen comprises approximately 1.8% of Cetera Trust Company N.A's portfolio, making the stock its 11th biggest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Nikulski Financial Inc. increased its holdings in shares of Amgen by 35.7% in the fourth quarter. Nikulski Financial Inc. now owns 2,710 shares of the medical research company's stock worth $781,000 after acquiring an additional 713 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in shares of Amgen by 1.1% in the fourth quarter. Handelsbanken Fonder AB now owns 367,586 shares of the medical research company's stock valued at $105,872,000 after purchasing an additional 3,830 shares during the last quarter. CWM LLC grew its stake in shares of Amgen by 1.3% in the fourth quarter. CWM LLC now owns 122,898 shares of the medical research company's stock valued at $35,397,000 after acquiring an additional 1,627 shares in the last quarter. Obsidian Personal Planning Solutions LLC grew its stake in shares of Amgen by 6.7% in the fourth quarter. Obsidian Personal Planning Solutions LLC now owns 881 shares of the medical research company's stock valued at $254,000 after acquiring an additional 55 shares in the last quarter. Finally, Criterion Capital Advisors LLC acquired a new position in shares of Amgen in the 4th quarter valued at approximately $2,553,000. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AMGN shares. UBS Group decreased their price target on shares of Amgen from $314.00 to $284.00 and set a "neutral" rating on the stock in a report on Wednesday. Truist Financial restated a "buy" rating and set a $320.00 price objective on shares of Amgen in a report on Friday, April 12th. The Goldman Sachs Group increased their price target on shares of Amgen from $313.00 to $350.00 and gave the company a "buy" rating in a research report on Wednesday, February 7th. Morgan Stanley lowered their price target on shares of Amgen from $281.00 to $278.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 7th. Finally, Leerink Partnrs downgraded shares of Amgen from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $296.95.

Amgen Trading Up 2.4 %

Amgen stock traded up $6.18 during mid-day trading on Friday, reaching $268.93. 3,380,330 shares of the company traded hands, compared to its average volume of 2,077,465. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm's 50 day moving average price is $276.90 and its 200 day moving average price is $281.51. The firm has a market capitalization of $144.25 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 2.50 and a beta of 0.58. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analysts' expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen's revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.09 EPS. On average, analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen's dividend payout ratio is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.